General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results | accesswire.com • |
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference | accesswire.com • |
Edesa Biotech to Participate in Upcoming Investor Conferences | accesswire.com • |
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference | accesswire.com • |
Edesa Biotech to Participate in Barclays Global Healthcare Conference | accesswire.com • |
Edesa Biotech to Participate in Upcoming Dermatology Meetings | accesswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-10 | 2024-03 | -0.69 | -0.58 | 0.11 | 15.94% |
2024-02-09 | 2023-12 | -1.21 | -0.54 | 0.67 | 55.37% |
2023-12-15 | 2023-09 | -0.71 | N/A | N/A | N/A |
2023-08-09 | 2023-06 | -1.19 | -0.7 | 0.49 | 41.18% |
2023-05-11 | 2023-03 | -1.19 | -0.84 | 0.35 | 29.41% |
2023-02-10 | 2022-12 | -1.33 | -0.91 | 0.42 | 31.58% |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-08-03 | BROOKS MICHAEL J PH.D. | President | 123.68K | Stock Award(Grant) |
2020-11-08 | JOHNSON LORIN KEITH | Director | 12.79K | Conversion of Exercise of derivative security |
2023-08-03 | LEMIEUX STEPHEN | Chief Financial Officer | 17.40K | Stock Award(Grant) |
2019-07-25 | MACDONALD SEAN ARTHUR | Director | 14.37K | Stock Award(Grant) |
2022-11-01 | NIFFENEGGER KATHI CPA | Chief Financial Officer | 0.00 | Stock Award(Grant) |
2024-03-31 | NIJHAWAN PARDEEP | Chief Executive Officer | 570.49K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Velan Capital Investment Management LP | 183.09K | 1.04M | 0.87% |
2023-06-29 | CM Management, LLC | 53.57K | 304.08K | 0.25% |
2023-06-29 | Vanguard Group Inc | 15.84K | 89.91K | 0.08% |
2023-06-29 | Geode Capital Management, LLC | 12.39K | 70.30K | 0.06% |
2023-06-29 | Cibc World Markets, Inc. | 7.80K | 44.30K | 0.04% |
2023-06-29 | State Street Corporation | 6.28K | 35.66K | 0.03% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 15.18K | 86.17K | 0.07% |
2023-05-30 | Fidelity Extended Market Index Fund | 5.71K | 36.37K | 0.03% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 2.83K | 18.00K | 0.01% |
2023-05-30 | Fidelity Series Total Market Index Fund | 2.08K | 13.25K | 0.01% |
2023-05-30 | Fidelity Total Market Index Fund | 1.20K | 7.66K | 0.01% |
Split | Date |
---|---|
1 : 7 | 2023-10-11 |
1 : 6 | 2019-06-10 |
1 : 7 | 2018-05-07 |
1 : 10 | 2015-09-02 |
solid hold
no 1 selling
Sold at 11$
ATER the real sqeeze
Your guys might want to check out CLVS. Canada government gave this company $45 million to make China’s Cov-19 vaccine. It’s shares around $3.40. Why should you put all your money in one basket. Good luck to all. I really hate to see dilution & Manipulation but we are small fish. What’s else can we do? Just hang in there.
$EDSA just want this to get to 7 so I can sell and then back down to 5 to rack up something big is coming
$EDSA are you kidding me
HOLD strong guys. The weak hands sold off.
Day Trader is OUT
On clinical trials website estimated begin date for EB05 is September , could be around the corner !
FDA will approve or reject the request . They have at least 30 days to review , not 30 days to approve. Should be coming soon
Price target is 33.00 $EDSA
$EDSA back to 19+
Great opportunity to average down if you bought high at opening